Uncommon EGFR Mutations in Non–Small Cell Lung Cancer - Episode 5

Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

Partner | Cancer Centers | <b>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</b>

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

EP. 1: Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP. 2: Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP. 3: Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP. 4: Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
Now Viewing
EP. 5: Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP. 6: Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP. 7: Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP. 8: Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP. 9: Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP. 10: Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
EP. 11: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
EP. 12: Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, director of Thoracic Oncology, and professor of oncology, Johns Hopkins Medicine, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Patients with EGFR exon 20 insertion mutations are not typically sensitive to the same TKIs that have demonstrated efficacy in patients with EGFR exon 19 or exon 21 mutations, Brahmer explains.

Osimertinib (Tagrisso) may have utility in patients with EGFR exon 20–mutant lung cancer when given daily at a dose of 160 mg, Brahmer says. Additionally, other monoclonal antibodies and TKIs have demonstrated initial clinical activity in this subgroup of patients; however, it is not yet clear whether these targeted approaches will be superior to chemotherapy, concludes Brahmer.